To summarize, the present study suggests that changes in cytokine levels (IL-1β, IL-2, IL-6, and TNF-α) could serve as biomarkers for predicting treatment response and prognosis in patients with HNSCC. The gene discussed is IL2; the disease is head and neck squamous cell carcinoma.